Certara, a provider of model-informed drug development, has announced the launch of D360 v10.5, the first in a series of releases focused on delivering biologic-relevant tools together with D360’s world-class data access capabilities.
This latest release of Certara’s D360 self-service data informatics platform upgrades the efficiency and consistency of data-driven biologics research workflows for drug discovery scientists, adds a new multi-parameter scoring capability, and improves data analysis and visualisation across all modalities.
With the advent of recombinant DNA technology and biomanufacturing, therapeutic discovery projects increasingly centre on biologic modalities, especially oligonucleotides. The worldwide biologic drugs market is estimated to be valued at more than $200 billion, growing at a rate of 10 per cent per year.1 While informatics systems for capturing biologics data are maturing, scientists often lack the tools required to understand and prioritise these entities efficiently, relying on manually-curated spreadsheets for crucial decision making.
‘While many of our customers use D360 for biologics and small molecule research already, this latest release delivers discovery tools that significantly strengthen the platform’s oligonucleotide capabilities and workflows. We have also incorporated feedback from thousands of D360 users to fine-tune workflows and usability across modality types, allowing scientists to focus on the data and science instead of the software they are using,’ said David Lowis, DPhil, senior director of D360 at Certara.
D360 v10.5’s new discovery research capabilities for biologics include:
- Oligonucleotide search by composition and similarity
- Oligonucleotide sequence rendering and formatting
- Oligonucleotide sequence filtering by composition and similarity
- Searching, filtering and rendering of HELM (Hierarchical Editing Language for Macromolecules)
In addition, D360 v10.5 features modality-independent, flexible, multi-parameter scoring that takes all relevant parameters into account and balances them against each other so that the best candidates can be identified quickly and consistently. Scientists can create, save, reuse, and share multi-parameter scoring functions that assess an array of multiple molecular properties to ensure efficacy, bioavailability and safety.
Certara also continues to enhance D360’s visualisation features so that scientists can easily understand data’s meaning in a therapeutic context. The ability to visualise trends and their relationship to the compounds being tested allows more rapid understanding of structure-activity relationships leading to improved decisions on project direction.
Reference
1. https://www.pharmasalmanac.com/articles/biologics-driving-force-in-pharma
